We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

BODITECH

Boditech Med Inc. develops products for in-vitro diagnostics and diagnostic reagents. Its products include automatic ... read more Featured Products: More products

Download Mobile App




Novel Point-Of-Care Procalcitonin Assay Performance Analyzed

By LabMedica International staff writers
Posted on 11 Dec 2019
There is a growing use of procalcitonin (PCT) measurements as a mean to diagnose and manage sepsis and PCT emerged as a useful tool to manage it accordingly, particularly in the emergency department (ED) and intensive care units (ICU).

PCT has a fair diagnostic accuracy for bacteremia in adult, neonates, infants, and children, hospitalized patients suspected of infection or sepsis. More...
Low procalcitonin levels can be used to rule out the presence of bacteremia. All commercial quantitative assays use the same ‘sandwich enzyme-linked immunosorbent assay (ELISA) principle to quantify PCT by forming antibody–procalcitonin–antibody complexes.

Scientists connected with the Hospital Center Université de Montpellier (Montpellier, France) analyzed the performance of the AFIASPCT Plus assay that was conducted using the AFIAS-6 instrument (Boditech, Dongnae-myeon, Republic of Korea). The AFIAS PCT Plus assay is a fluorescence immunoassay that quantifies PCT concentration in serum, plasma and whole blood (10–50 μL) drawn from a finger or heel using a capillary tip. The AFIAS-6 point of care (POC) assay uses an all-in-one cartridge which automates the entire procedure from sample preparation to test. PCT levels were determined using the BRAHMS PCT assay (B·R·A·H·M·S GmbH, Hennigsdorf, Germany), which is routinely used at the central laboratory.

Analytical performances including imprecision studies, limit of blank (LoB), limit of detection (LoD) and limit of quantification (LOQ) were determined. The method comparison was performed using plasma versus whole blood for the BRAHMS Kryptor CompactPlus versus AFIAS-6, respectively. The scientists reported that the total imprecision was far from the coefficient of variation (CV) of 4.5% claimed by the manufacturer and close to 10%, for levels of PCT at 0.4 and 8.3 μg/L. The LoD of this novel PCT assay was found to close to the LoD provided by the manufacturer at 0.04 μg/L. The LOQ was higher than that claimed by the manufacturer (0.1 versus 0.002, respectively). Correlation studies showed a good correlation between PCT measurements using plasma on Kryptor system and on corresponding whole blood with POC reaching a bias of −0.04 in the range from 0.02 to 2 μg/L.

The authors concluded that the novel PCT assay on AFIAS-6 is an acceptable POC alternative for the diagnosis and management of sepsis at EDs to improve the flow of patients, as results are consistent with those of the standard PCT Kryptor Compact Plus assay, despite its higher imprecision. The study was available online since October 26, 2019 in the journal Practical Laboratory Medicine.

Related Links:
Hospital Center Université de Montpellier
Boditech
B·R·A·H·M·S GmbH



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Urine Analyzer
respons® UDS100
New
Drug Testing Assays
Atellica DT 250 Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Age-Based Genetic Testing May Miss Most Inherited Cancer Risk Variants

Inherited cancer risk can influence diagnosis, treatment planning, and family screening, yet current testing practices often depend on a patient’s age at diagnosis. Many patients undergo germline genetic... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.